Comparison · NCT02936752-ea38bf4b
Treatment (Entinostat, Pembrolizumab) Dose Level 1 vs Treatment (Entinostat, Pembrolizumab) Dose Level 2: Maximum Tolerated Dose of Entinostat Given in Combination With Pembrolizumab
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Treatment (Entinostat, Pembrolizumab) Dose Level 1 vs Treatment (Entinostat, Pembrolizumab) Dose Level 2: Maximum Tolerated Dose of Entinostat Given in Combination With Pembrolizumab. Trial comparisons, record NCT02936752-ea38bf4b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02936752-ea38bf4b
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.143 | 0.0257 | 0.513 | wilson | |
| Risk in group 2 | 0.333 | 0.0968 | 0.7 | wilson | |
| Risk difference, group 1 minus group 2 | -0.19 | -0.575 | 0.249 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.429 | 0.0505 | 3.64 | log | |
| Odds ratio, group 1 over group 2 | 0.333 | 0.0221 | 5.03 | log | |
| Number needed to treat, for one fewer participant with the outcome on Treatment (Entinostat, Pembrolizumab) Dose Level 1 than on Treatment (Entinostat, Pembrolizumab) Dose Level 2 | 5.25 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Treatment (Entinostat, Pembrolizumab) Dose Level 1 | Patients receive lower dose entinostat PO on days 1 and 8 or higher dose entinostat PO on days 1, 8, and 15, and pembrolizumab IV over 30 minutes on day 1 of cycle 2 and cycles thereafter. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve an objective response or maintain a SD status after the first 4 cycles may continue to receive entinostat and pembrolizumab for up to 1 year.~Entinostat: Given PO~Pembrolizumab: Given IV | 1 | 7 | OG000 |
| Group 2 | Treatment (Entinostat, Pembrolizumab) Dose Level 2 | Patients receive lower dose entinostat PO on days 1 and 8 or higher dose entinostat PO on days 1, 8, and 15, and pembrolizumab IV over 30 minutes on day 1 of cycle 2 and cycles thereafter. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve an objective response or maintain a SD status after the first 4 cycles may continue to receive entinostat and pembrolizumab for up to 1 year.~Entinostat: Given PO~Pembrolizumab: Given IV | 2 | 6 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Maximum Tolerated Dose of Entinostat Given in Combination With Pembrolizumab
- Description
Toxicities will be tabulated and graded according to the Common Terminology Criteria for Adverse Events version 5. Dose-limiting toxicities will be assessed after the first 2 cycles of combined therapy. Presented are the counts of participants that experienced DLT in the period up to 42 days.
- Time frame
- Up to 42 days
- Population
- 13 participants were eligible for dose escalation.
Source ClinicalTrials.gov
Trial
- Title
- Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents
- NCT number
- NCT02936752
- Phases
- PHASE1
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Entinostat, Pembrolizumab
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2024-10-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02936752?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02936752-ea38bf4b